Answers are grounded in this paper and cite their sources.
A genotyping study of 285 Hybrid Capture 2 low-risk probe cocktail-positive specimens showed cross-reactivity with several untargeted human papillomavirus genotypes. Cross-reactivity was often clinically beneficial due to the detection of untargeted low-risk genotypes. A total of 8.4% of positive results, usually weak, were due to cross-reactivity with high-risk genotypes. Establishment of a gray zone is recommended.
No takes yet. Share an insight, caveat, or question.
Poljak et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: